← Trials/Trial dossier/NCT00042172

CompletedPhase 4

Treatment for Early Memory Loss

Cognitive Enhancers Explored With PET Imaging

Lead sponsor

University of Iowa

Asset

Donepezil

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criterion

•Age ≥65

Primary endpoint

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00042172

Org study IDR21MH061801https://reporter.nih.gov/quickSearch/R21MH061801

NihR21MH061801

Timeline

Milestones

Study start2002-06 (month precision)

Study first posted2002-07-26estimated

Primary completion2004-09actual (month precision)

Study completion2004-09actual (month precision)

Last update posted2014-03-03estimated

Assets

Drug assets

Donepezil

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Display impairment on at least 2 of 3 memory tests

•Meet the following criteria for mild cognitive impairment: subjective complaint of memory problems; no impairment in activities of daily living; general cognitive function in the normal age-adjusted range; abnormal memory function for age; and lacking full DSM criteria for dementia

Exclusion criteria

•Have a history of major neurological, metabolic, psychiatric or cardiovascular disease (patients with a history of non-CNS oncologic disease treated surgically and currently in remission will not be excluded)

•Have a cerebrovascular condition

•Abuse alcohol or drugs

•Have renal or hepatic disease, diabetes mellitus, gout, or adrenocortical insufficiency

•Are sensitive to carbonic anhydrase inhibitors, antibacterial sulfonamides, thiazide diuretics, or other sulfonamide-derivative diuretics

•Have taken donepezil or GBE products prior to enrollment

•Have taken medications, including herbal agents (exceptions will be made for routine health maintenance medications such as alendronate [Fosamax] for osteoporosis, vitamin therapy [not to exceed 200 percent RDA for any particular vitamin], thyroid replacement therapy, hormone replacement, and ophthalmic medications for glaucoma and other eye disorders)

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.